{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:03:13Z","timestamp":1788386593907,"version":"build-2803163510"},"reference-count":30,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Instituto de Salud Carlos III (ISCIII)","award":["PI20\/01052"],"award-info":[{"award-number":["PI20\/01052"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Multidisciplinary strategies have transformed the management of advanced ovarian cancer. We aimed to evaluate the effectiveness of paclitaxel in hyperthermic intraperitoneal chemotherapy (HIPEC) following surgical cytoreduction for ovarian peritoneal metastases in a randomized phase III trial conducted between August 2012 and December 2019. Seventy-six patients were randomized to either the HIPEC or no HIPEC group. Although median values for the primary endpoints (recurrence-free survival (RFS) and overall survival (OS)) revealed superior outcomes for the HIPEC (RFS: 23 months, OS: 48 months) over the control group (RFS: 19 months, OS: 46 months), these differences were not statistically significant (p = 0.22 and p = 0.579). Notably, the HIPEC group demonstrated significantly higher 5-year OS and 3-year RFS rates (47.2% and 47.5%) compared to patients without HIPEC (34.5% and 21.3%). Stratification according to Peritoneal Surface Disease Severity Score (PSDSS) showed improved OS and RFS for patients with lower PSDSS (I\u2013II) in the HIPEC-treated group (p = 0.033 and p = 0.042, respectively). The Clavien\u2013Dindo classification of adverse event grades revealed no significant differences between HIPEC and controls (p = 0.482). While overall results were not statistically significant, our long-term follow-up emphasized the potential benefit of HIPEC-associated cytoreduction with paclitaxel, particularly in selected ovarian cancer patients with lower PSDSS indices.<\/jats:p>","DOI":"10.3390\/curroncol31020048","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T10:03:48Z","timestamp":1706177028000},"page":"660-671","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Paclitaxel as HIPEC-Drug after Surgical Cytoreduction for Ovarian Peritoneal Metastases: A Randomized Phase III Clinical Trial (HIPECOVA)"],"prefix":"10.3390","volume":"31","author":[{"given":"Pedro","family":"Villarejo Campos","sequence":"first","affiliation":[{"name":"Department of Surgery, Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital, Avda. Reyes Cat\u00f3licos, 2, 28040 Madrid, Spain"},{"name":"Department of Surgery, Universidad Aut\u00f3noma de Madrid, C\/Arzobispo Morcillo s\/n, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"S\u00e1nchez Garc\u00eda","sequence":"additional","affiliation":[{"name":"Department of Surgery, General University Hospital of Ciudad Real, C\/Obispo Rafael Torija, s\/n, 13005 Ciudad Real, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0956-2531","authenticated-orcid":false,"given":"Mariano","family":"Amo-Salas","sequence":"additional","affiliation":[{"name":"Department of Mathematics, University of Castilla-La Mancha, Camino de Moledores, s\/n, 13071 Ciudad Real, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Garc\u00eda Santos","sequence":"additional","affiliation":[{"name":"Department of Surgery, General University Hospital of Ciudad Real, C\/Obispo Rafael Torija, s\/n, 13005 Ciudad Real, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"L\u00f3pez de la Manzanara","sequence":"additional","affiliation":[{"name":"Department of Gynaecology, General University Hospital of Ciudad Real, C\/Obispo Rafael Torija, s\/n, 13005 Ciudad Real, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Alberca","sequence":"additional","affiliation":[{"name":"Department of Surgery, General University Hospital of Ja\u00e9n, 23007 Ja\u00e9n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Padilla-Valverde","sequence":"additional","affiliation":[{"name":"Department of Surgery, General University Hospital of Ciudad Real, C\/Obispo Rafael Torija, s\/n, 13005 Ciudad Real, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7044-0154","authenticated-orcid":false,"given":"Francisco Javier","family":"Redondo Calvo","sequence":"additional","affiliation":[{"name":"Department of Anaesthesia, General University Hospital of Ciudad Real, C\/Obispo Rafael Torija, s\/n, 13005 Ciudad Real, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Mart\u00edn","sequence":"additional","affiliation":[{"name":"Department of Surgery, General University Hospital of Ciudad Real, C\/Obispo Rafael Torija, s\/n, 13005 Ciudad Real, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1093\/jnci\/djj443","article-title":"Survival benefits with diverse chemotherapy regimens for ovarian cancer: Meta-analysis of multiple treatments","volume":"98","author":"Kyrgiou","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1515\/pp-2017-0010","article-title":"Pharmacological principles of intraperitoneal and bidirectional chemotherapy","volume":"2","author":"Michelakis","year":"2017","journal-title":"Pleura Peritoneum"},{"key":"ref_4","first-page":"CD005340","article-title":"Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer","volume":"2016","author":"Jaaback","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1245\/s10434-012-2784-6","article-title":"Hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis: Role of heat shock proteins and dissecting effects of hyperthermia","volume":"20","author":"Pelz","year":"2013","journal-title":"Ann. Surg. Oncol."},{"key":"ref_6","first-page":"610597","article-title":"Peritoneal carcinomatosis: Intraoperative parameters in open (coliseum) versus closed abdomen HIPEC","volume":"2015","author":"Halkia","year":"2015","journal-title":"Int. J. Surg. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Yurttas, C., Hoffmann, G., Tolios, A., Haen, S.P., Schwab, M., K\u00f6nigsrainer, I., K\u00f6nigsrainer, A., Beckert, S., and L\u00f6ffler, M.W. (2018). Systematic Review of Variations in Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Metastasis from Colorectal Cancer. J. Clin. Med., 7.","DOI":"10.3390\/jcm7120567"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1080\/14656566.2020.1766024","article-title":"An overview and update of hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"21","author":"Michelakis","year":"2020","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer","volume":"378","author":"Koole","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1245\/s10434-014-4157-9","article-title":"Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: A prospective randomized phase III study","volume":"22","author":"Spiliotis","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S231","DOI":"10.21037\/jgo-2020-03","article-title":"Intraperitoneal paclitaxel: Pharmacology, clinical results and future prospects","volume":"12","author":"Sugarbaker","year":"2021","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1245\/s10434-007-9792-y","article-title":"Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: A clinical and pharmacokinetic study","volume":"15","author":"Rosing","year":"2008","journal-title":"Ann. Surg. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1245\/s10434-014-3599-4","article-title":"Treatment of microscopic disease with hyperthermic intraoperative intraperitoneal chemotherapy after complete cytoreduction improves disease-free survival in patients with stage IIIC\/IV ovarian cancer","volume":"21","author":"Gil","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/jso.20597","article-title":"Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer","volume":"94","author":"Rubio","year":"2006","journal-title":"J. Surg. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.suronc.2016.05.010","article-title":"Hyperthermic intraperitoneal chemotherapy with paclitaxel or cisplatin in patients with stage III-C\/IV ovarian cancer. Is there any difference?","volume":"25","author":"Gil","year":"2016","journal-title":"Surg. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s12094-019-02065-3","article-title":"The use of cisplatin plus doxorubicin or paclitaxel in hyperthermic intraperitoneal chemotherapy (HIPEC) for stage IIIC or IV epithelial ovarian cancer: A comparative study","volume":"21","author":"Manzanedo","year":"2019","journal-title":"Clin. Transl. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00404-014-3153-4","article-title":"Security and efficiency of a closed-system, turbulent-flow circuit for hyperthermic intraperitoneal chemotherapy after cytoreductive ovarian surgery: Perioperative outputs","volume":"290","year":"2014","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.surg.2013.12.005","article-title":"Experimental development of an intra-abdominal chemohyperthermia model using a closed abdomen technique and a PRS-1.0 Combat CO2 recirculation system","volume":"155","year":"2014","journal-title":"Surgery"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1080\/02656736.2016.1237679","article-title":"Usefulness of thermographic analysis to control temperature homogeneity in the development and implementation of a closed recirculating CO2 chemohyperthermia model","volume":"33","year":"2017","journal-title":"Int. J. Hyperth."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5239","DOI":"10.2147\/CMAR.S277912","article-title":"Effective Strategies to Predict Survival of Colorectal Peritoneal Metastases Patients Eligible for Cytoreductive Surgery and HIPEC","volume":"13","author":"Simkens","year":"2021","journal-title":"Cancer Manag. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/jso.24406","article-title":"The American Society of Peritoneal Surface Malignancies Multi-Institution evaluation of 1,051 advanced ovarian cancer patients undergoing cytoreductive surgery and HIPEC: An introduction of the peritoneal surface disease severity score","volume":"114","author":"Foster","year":"2016","journal-title":"J. Surg. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.suronc.2018.11.005","article-title":"Validation of a peritoneal surface disease severity score in stage IIIC-IV ovarian cancer treated with cytoreduction and hyperthermic intraperitoneal chemotherapy","volume":"28","author":"Elena","year":"2019","journal-title":"Surg. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3802\/jgo.2015.26.2.87","article-title":"FIGO\u2019s staging classification for cancer of the ovary, fallopian tube, and peritoneum: Abridged republication","volume":"26","author":"Prat","year":"2015","journal-title":"J. Gynecol. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1245\/s10434-020-08649-6","article-title":"The Peritoneal Cancer Index is a Strong Predictor of Incomplete Cytoreductive Surgery in Ovarian Cancer","volume":"28","author":"Lomnytska","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_25","first-page":"CD007565","article-title":"Optimal primary surgical treatment for advanced epithelial ovarian cancer","volume":"8","author":"Elattar","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_26","first-page":"CD008765","article-title":"Surgical cytoreduction for recurrent epithelial ovarian cancer","volume":"2","author":"Lopes","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamasurg.2022.0143","article-title":"Survival after Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial","volume":"157","author":"Lim","year":"2022","journal-title":"JAMA Surg."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1245\/s10434-021-11087-7","article-title":"Cytoreductive Surgery With or Without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer: A Phase 3 Clinical Trial","volume":"29","author":"Antonio","year":"2022","journal-title":"Ann. Surg. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.21.00605","article-title":"Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study","volume":"39","author":"Zivanovic","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s13193-016-0504-6","article-title":"Complications of Cytoreductive Surgery and HIPEC in the Treatment of Peritoneal Metastases","volume":"7","author":"Mehta","year":"2016","journal-title":"Indian J. Surg. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/2\/48\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:48:28Z","timestamp":1760104108000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/2\/48"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,24]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["curroncol31020048"],"URL":"https:\/\/doi.org\/10.3390\/curroncol31020048","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,24]]}}}